Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Exclusion Criteria

• •Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.
• •Known hypersensitivity to \[¹⁸F\]FAPI-74.
• •Administration of another investigational therapeutic or diagnostic product within 30 days prior to \[¹⁸F\]FAPI-74 administration.
• •Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \[¹⁸F\]FAPI-74 administration.
• •Previous cancer diagnosis (except basal cell carcinoma of the skin or in situ carcinoma of the cervix/uterus). Participants treated with curative intent and disease-free for more than 5 years are permitted.
• •Hepatic function: T. bili \>1.5X ULN or alk phos, ALT, or AST \>5X ULN
• •Renal function: GFR \< 30 mL/min
• •Pregnant or breast feeding (a negative pregnancy test is required in women of childbearing potential)
• •Inability to undergo the PET/CT scanning procedure.
• •Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
• •Sarcoidosis
• •Treatment, including chemotherapy, radiation or surgery for curative intent of PDAC.